COLOMBO NICOLETTA

Ruolo: 
professore associato
Settore scientifico disciplinare: 
GINECOLOGIA E OSTETRICIA (MED/40)

Pubblicazioni

  • Vergote, I., Scambia, G., O'Malley, D., Van Calster, B., Park, S., Del Campo, J., et al. (2019). Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY. Dettaglio
  • Colombo, N., Sessa, C., du Bois, A., Ledermann, J., Mccluggage, W., Mcneish, I., et al. (2019). ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. ANNALS OF ONCOLOGY. Dettaglio
  • Matulonis, U., Shapira-Frommer, R., Santin, A., Lisyanskaya, A., Pignata, S., Vergote, I., et al. (2019). Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. ANNALS OF ONCOLOGY. Dettaglio
  • Colombo, N., Sessa, C., Bois, A., Ledermann, J., Mccluggage, W., Mcneish, I., et al. (2019). ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 29(4), 728-760. Dettaglio
  • Heitz, F., Harter, P., Åvall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., et al. (2019). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. GYNECOLOGIC ONCOLOGY, 152(2), 235-242. Dettaglio